Overcoming TKI resistance in chronic myeloid leukemia via STAT5A disruption

CRISPR/Cas9-mediated deletion of the transcription factor STAT5A restores apoptosis in drug-resistant cells, addressing the persistent failure of kinase inhibitors. This mechanism bypasses the BCR::ABL1 mutations that typically drive TKI resistance in chronic myeloid leukemia. While standard treatments focus on inhibiting protein activity, this method removes the genetic instruction entirely, preventing the cell from activating survival bypasses.

Mechanisms of TKI resistance in chronic myeloid leukemia

Current clinical management relies on tyrosine kinase inhibitors (TKIs), yet patients frequently develop resistance through secondary mutations or alternative signalling pathways. STAT5A functions as a principal downstream effector of the BCR::ABL1 fusion protein, maintaining cell viability even when the primary oncogene is suppressed. The persistence of STAT5A signalling remains a major barrier to achieving deep molecular responses in advanced cases. Researchers targeted STAT5A in K562 cell lines, including variants specifically resistant to imatinib and ponatinib. Using XTT assays and Annexin V/PI staining, the team measured a sharp decline in cell viability and a corresponding increase in programmed cell death. Flow cytometry confirmed G0/G1 phase arrest, indicating that the loss of STAT5A effectively halts the cell cycle. RT-qPCR quantification revealed that STAT5A knockout also dysregulates JAK2 and STAT3, suggesting a compensatory feedback loop within the JAK/STAT pathway. Bioinformatic validation via TRRUST and ChEA3 databases suggests that STAT5A directly regulates CDKN2B, BCL2L1, and CCND1. This identifies STAT5A as a central node that could be targeted to neutralise escape routes used by malignant cells. However, this research does not address whether the same efficacy holds in the complex microenvironment of human bone marrow or in non-K562 lineages. Future validation in patient-derived CD34+ cells is required to organise these findings into a viable clinical strategy.